Optimal Insertion Time During Remimazolam-Remifentanil Anesthesia for Painless Gastroscopy
Optimal Insertion Time During Remimazolam-Remifentanil Anesthesia for Painless Gastroscopy: A Single-Center Randomized Controlled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Guangdong
-
Huizhou, Guangdong, China
- Huizhou First People's Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- ASA physical status Ⅰ/Ⅱ, BMI 18-24kg/m², scheduled for elective diagnostic painless gastroscopy
Exclusion Criteria:
- (1) Allergy to remimazolam, remifentanil, BZDs, or opioids; (2) Difficult airway (Mallampati class Ⅲ/Ⅳ,limited mandibular movement, or restricted neck extension);(3)Severe cardiovascular/cerebrovascular/respiratory/hepatic/renal dysfunction;(4)Pregnancy/lactation;(5)Chronic use of sedatives/analgesics/psychotropic drugs; (6) Preoperative pulmonary infection/respiratory failure; (7) Inability to provide informed consent or complete follow-up.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: G group
The timing point for gastroscope insertion was defined as when the patient's mandible was lifted, no motor response was observed any longer, and the h
|
Intravenous sedation and analgesia with remimazolam combined with remifentanil.
Endoscope insertion is performed when jaw reflex is absent and heart rate is stable.
|
|
Active Comparator: C group
The timing point for gastroscope insertion was determined when the corneal reflex was absent.
|
Intravenous sedation and analgesia with remimazolam combined with remifentanil.
Endoscope insertion is performed when eyelash reflex is absent.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cough
Time Frame: From start of endoscope insertion until completion of gastroscopy
|
Incidence of coughing during endoscope insertion and examination
|
From start of endoscope insertion until completion of gastroscopy
|
|
Body movement
Time Frame: From start of endoscope insertion until completion of gastroscopy
|
Incidence of body movement
|
From start of endoscope insertion until completion of gastroscopy
|
|
Hypotension
Time Frame: From start of endoscope insertion until completion of gastroscopy
|
Incidence of hypotension
|
From start of endoscope insertion until completion of gastroscopy
|
|
Bradycardia
Time Frame: From start of endoscope insertion until completion of gastroscopy
|
Incidence of bradycardia
|
From start of endoscope insertion until completion of gastroscopy
|
|
Hypoxemia
Time Frame: From start of endoscope insertion until completion of gastroscopy
|
Incidence of hypoxemia
|
From start of endoscope insertion until completion of gastroscopy
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Endoscopist satisfaction score
Time Frame: Immediately after completion of gastroscopy
|
Endoscopist satisfaction score
|
Immediately after completion of gastroscopy
|
|
PACU discharge time
Time Frame: From admission to PACU until discharge from PACU
|
Time to discharge from PACU
|
From admission to PACU until discharge from PACU
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Jianhao Zeng, MD, Huizhou First People's Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- KYLL-2024-023-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.